Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxart, Inc. - Common Stock (NQ:VXRT)

0.3200 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Watch Out for a Selloff in Vaxart Stock ↗
VXRT stock's price may drop as their oral inoculation waits in the wings while other vaccine manufacturers take over the market. 
Via InvestorPlace
News headline image
Vaxart Inks Antiviral Asset Licensing Pact With Altesa Biosciences ↗
Vaxart Inc (NASDAQ: VXRT) has granted Altesa Biosciences Inc an exclusive worldwide license to develop and commercialize Vaxart's patented... 
Via Benzinga
News headline image
Vaxart Stock Could Make Another Big Return in the Future ↗
It might be tempting to dismiss VXRT stock now that other Covid-19 vaccines are available, but pill-based vaccines for diseases are appealing. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021 ↗
Upgrades For Taiwan Semiconductor Manufacturing Co Ltd (NYSE: 
Via Benzinga
Why Vaxart Shares Are Trading Higher Today ↗
Vaxart Inc (NASDAQ:VXRT) shares are trading higher by 30% ... 
Via Benzinga
News headline image
Will the Promise of Avoiding the Needle Pay Off for Vaxart? ↗
VXRT stock just received a buy recommendation and a $13 price target from Jefferies, based on the promise of a oral vaccine instead of a needle. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021 ↗
Upgrades Zelman upgraded the previous rating for Armstrong World Industries Inc (NYSE: 
Via Benzinga
News headline image
Is Now The Time To Buy Stock Or Options In Apple, PayPal, Square Or Vaxart? ↗
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
News headline image
VXRT Stock: Can Redditors Help Vaxart Power Higher? ↗
Today, VXRT stock is climbing higher on an otherwise red day for the markets, as many speculate retail investors could be behind this rise. 
Via InvestorPlace
News headline image
Vaxart Is Still Not Worth Anywhere Near Its Present Price ↗
Vaxart is still not worth today's price. VXRT stock is worth no more than $6, especially if it's going to need another capital raise. 
Via InvestorPlace
News headline image
Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today ↗
The declines appear to be caused simply by volatility that's common with small biotech stocks. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vaxart Stock? ↗
The science looks fishy for this small-cap biotech. 
Via The Motley Fool
News headline image
Meme Stocks Continue To Surge As Traders Move To Biotech ↗
The meme stock crowd turned its attention to biotech and healthcare stocks, boosting some shares by as much as 10%. 
Via Talk Markets
News headline image
64 Biggest Movers From Friday ↗
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
News headline image
VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today ↗
VXRT stock is on the move as the company received some very bullish coverage from an analyst initiating coverage today. 
Via InvestorPlace
News headline image
Most Active Equity Options For Midday - Friday, June 11 ↗
Top tickers for midday: AMC, AAPL, TSLA, NIO, NVDA, AMZN, CLOV, SNAP, CLF, GME, PLTR, VXRT, AMD, MO, F, SENS, BAC, MSFT, BB, ET. 
Via Talk Markets
News headline image
Nasdaq, S&P 500 Eye Weekly Wins as Bond Yields Retreat ↗
The 10-year Treasury bond yield fell to a three-month low. 
Via Talk Markets
Topics Bonds Stocks
News headline image
46 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67... 
Via Benzinga
Topics Initial Public Offering
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, Novan's stock is trading at a volume of 109.3 million,... 
Via Benzinga
News headline image
Why Vaxart Stock Is Skyrocketing Today ↗
Investors are cheering an analyst's positive recommendation. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021 ↗
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
News headline image
Why Shares of Vaxart Plummeted 38.6% in May ↗
This isn't the first time its coronavirus vaccine pill has disappointed investors. 
Via The Motley Fool
News headline image
Bet on a No-Needle Vaccine Strategy with Vaxart ↗
Reimagining Covid-19 vaccines isn't an easy task, but Vaxart is prepared to innovate - and VXRT stock could move higher at any given moment. 
Via InvestorPlace
News headline image
10 More Current & Former Penny Stocks With High Short Interest ↗
High Short Interest Stocks Are Something Traders Are On The Hunt For & Here's Another 10 
Via Talk Markets
News headline image
28 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Aytu Biopharma, Inc. (NASDAQ: AYTU) rose 37.8% to $7.40 in pre-market trading. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) rose 23.5% to $3.89 in pre-market trading... 
Via Benzinga
News headline image
5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street ↗
If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year. 
Via The Motley Fool
Topics Economy
News headline image
These Vaccine Latecomers Could Still Win Big. Here's How ↗
The key is standing out from the crowd. 
Via The Motley Fool
Topics Cannabis
News headline image
Vaxart’s Compelling Story Will Take a Long Time to Play Out ↗
As a company attempting to make oral vaccines, Vaxart has a compelling story. However VXRT stock looks to be many years away from paying off. 
Via InvestorPlace
News headline image
With Fading Covid-19 Infections, Vaxart’s Relevance Is Waning ↗
Prior to the vaccination rollout from Vaxart’s competitors, VXRT stock appeared a compelling alternative. That’s no longer the case. 
Via InvestorPlace
News headline image
Speculators Should Consider Buying Vaxart Stock ↗
Vaxart's vaccine pill could prove to be effective against the original Covid-19 virus and its new variants, sending VXRT stock sky-high. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.